Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis

CONCLUSION: Retrospective real-world data show a significantly longer RPFS for mHSPC patients treated with ADT + AAP compared to ADT only or ADT + docetaxel at short-term follow-up. This can aid in counselling of mHSPC patients in daily clinical practice.PMID:34789066 | DOI:10.1080/17843286.2021.2001999

Source: Clinical Prostate Cancer - November 18, 2021 Category: Cancer & Oncology Authors: E Lambert S Hollebosch C van Praet S Van Bruwaene L Duck W De Roock S van Wambeke C Ghysel F Ameye P Schatteman F Vandenbroucke B Sautois F Baekelandt D Ost K Fransis B Filleul C Remondo W Wynendaele B Bamelis P Logghe E Vergauwe E Denies S Joniau N Lumen Source Type: research